![]() Halford failed to muster up the financial support to fund his research, so he conducted drug trials without the approval of the FDA. Rational Vaccines was the brainchild of Southern Illinois University professor William Halford, who’d been working on a herpes cure since 2007. This left hope in the hands of Rational Vaccines, a medical research company that had announced a successful 2016 drug trial for a live vaccine, Theravax, which treated both HSV-1 and HSV-2. Like Vical Incorporated, Genocea too had failed. In an official press release, the company said it was “exploring strategic alternatives” to the GEN-003 program. But in September 2017, the GEN-003 program was shuttered, with Genocea cutting its workforce by roughly 40%. Vaccine and immunotherapy company Genocea launched its GEN-003 drug trial with the hopes of discovering a cure for genital herpes. Sadly, based on the study’s disappointing results, Vical decided to terminate its entire HSV-2 program. Study participants did not see a significant reduction in recurrences during the trial period. But in June 2018, Vical announced the study had failed. The study seemed hopeful – it was double-blind, placebo-controlled, and randomized, and the study group was comprised of herpes patients that experienced 4-9 flareups in a given year. Vical Incorporated, a biopharmaceutical product developer, launched a clinical study in 2017 with the hopes of treating herpes simplex virus type 2 (HSV-2). ![]() Scrutiny aside, Synergy Pharmaceuticals has achieved something that many other companies have failed to do. What is more starting is considering Josh was himself a supporter and advocate for the Rational Vaccine study that was later brought under federal criminal investigation. ![]() Understandably, critics like Josh Bloom come as no surprise given his longstanding employment with Wyeth and then Pfizer. The conflict is especially controversial when discussing a potential cure for the most prevalent viral disease. It’s an age-old dispute, in which the medical community refuses to acknowledge the health impacts of natural treatments. The criticism stems not from ethical concerns about the drug’s effectiveness but from an industry-wide reluctance to embrace medications that aren’t pharmaceutical-based. In securing these partnerships, Synergy could take its business revenue to new heights and possibly quiet its critics. And to reach a scalable level of sales for millions of consumers, more companies need to buy in and support Synergy’s business. To ramp up its capacity, Synergy will need to form strong partnerships across the European sector. These queries are understandable, but there’s a simple solution. But its groundbreaking cure, the first-ever natural treatment option for the herpes simplex virus, has invited scrutiny from many critics, including the major medical associations.Īnd naturally, there are concerns about Synergy Pharmaceuticals’ ability to meet global demand for its product as word spreads. The company is making substantial headway across the Australian and Australasian markets and gaining a foothold in a highly competitive pharmaceutical marketplace. However, with only a few years on the market, Synergy Pharmaceuticals is a relatively small fish in a very big ocean.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |